SSA
RPRX icon

Sierra Summit Advisors’s Royalty Pharma RPRX Stock Holding History

Sierra Summit Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
20,842
-323
-2% -$16.8K 0.13% 112
2026
Q1 		$1.02M Buy
21,165
+924
+5% +$40.5K 0.15% 101
2025
Q4 		$782K Buy
20,241
+461
+2% +$17.6K 0.12% 127
2025
Q3 		$698K Buy
19,780
+420
+2% +$15.2K 0.11% 139
2025
Q2 		$698K Buy
+19,360
New +$641K 0.12% 120

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sierra Summit Advisors's RPRX Position: Q2 2026 in Review

Sierra Summit Advisors reduced its Royalty Pharma (RPRX) stake by 1.5% in Q2 2026, selling an estimated $16.8K and leaving 20,842 shares worth $1.17M. The position accounts for 0.13% of the portfolio, ranked #112.

Sierra Summit Advisors first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Sierra Summit Advisors held 20,842 shares of Royalty Pharma worth $1.17M as of Q2 2026.
  • Sierra Summit Advisors sold 323 Royalty Pharma shares in Q2 2026, an estimated $16.8K.
  • Royalty Pharma made up 0.13% of Sierra Summit Advisors's portfolio in Q2 2026, its #112 holding.
  • Sierra Summit Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sierra Summit Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.